Generic placeholder image

Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)

Editor-in-Chief

ISSN (Print): 1871-5222
ISSN (Online): 1875-6115

Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression

Author(s): Simon A. Jones, Gareth W. Jones, Anwen S. Williams and Mari A. Nowell

Volume 8, Issue 3, 2008

Page: [235 - 246] Pages: 12

DOI: 10.2174/187152208785748340

Price: $65

Abstract

The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohns disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.

Keywords: Cytokines, receptors, chemokines, inflammation, arthritis, leukocytes, gp130, tocilizumab


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy